A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity

Cancer Research

Volumn 73, Issue 1, 2013, Pages 265-275

  Guidugli, Lucia ^a   Pankratz, Vernon S ^a   Singh, Namit ^c   Thompson, James ^b   Erding, Catherine A ^a   Engel, Christoph ^d   Schmutzler, Rita ^e   Domchek, Susan ^f   Nathanson, Katherine ^f   Radice, Paolo ^g   Singer, Christian ^h   Tonin, Patricia N ⁱ   Lindor, Noralane M ^j   Goldgar, David E ^k   Couch, Fergus J ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j MAYO CLINIC   (United States)

^k UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CONTROLLED STUDY; DNA BINDING MOTIF; DNA REPAIR; DNA STRAND BREAKAGE; FEMALE; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOTE; HOMOLOGY DIRECTED REPAIR; HUMAN; MISSENSE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; FEMALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MODELS, STATISTICAL; MUTATION, MISSENSE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84871997956     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2081     Document Type: Article

References (30)

1. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72.
2. Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 2010;467:678-83.
3. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8.
4. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-66.
5. The Breast Cancer Information Core. An open access on-line breast cancer mutation data base. 1996; [cited 1996]. Available from: http://research.nhgri. nih.gov/bic/
6. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007;81:873-83.
7. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.
8. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 2006;66:2019-27.
9. Walker LC, Whiley PJ, Couch FJ, Farrugia DJ, Healey S, Eccles DM, et al. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 2010;31:E1484-505.
10. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295-305.
11. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 2008;29:1327-36.
12. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008;29:1282-91.
13. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008;68:3523-31.
14. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res 2010;70:4880-90.
15. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005;65:417-26.
16. Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N. Assessment of functional effects of unclassified genetic variants. Hum Mutat 2008;29:1314-26.
17. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat 2008;29:1342-54.
18. Vallee MP, Francy TC, Judkins MK, Babikyan D, Lesueur F, Gammon A, et al. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. Hum Mutat 2012;33:22-8.
19. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002;22:669-79.
20. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett 2006;27:861-74.
21. McLachlan GJ. Discriminant analysis and statistical pattern recognition. New York, NY: Wiley; 1992.
22. Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density estimation. J Am Stat Assoc 2002;97:611- 31.
23. Lindor NM, Guidugli L, Wang X, Vallee MP, Monteiro AN, Tavtigian S, et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 2012;33:8-21.
24. Freedman ML, Penney KL, Stram DO, Le Marchand L, Hirschhorn JN, Kolonel LN, et al. Common variation in BRCA2and breast cancer risk: a haplotype-based analysis in the Multiethnic Cohort. Hum Mol Genet 2004;13:2431-41.
25. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002;6:119-21.
26. Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, et al. Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet 1999;8:413-23.
27. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 2004;11:377-94.
28. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37:e67.
29. Yang H, Jeffrey PD, Miller J, Kinnucan E, Sun Y, Thoma NH, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002;297:1837-48.
30. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA- evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012;33:2-7.